Oregon Mesothelioma Fact Sheet

While mesothelioma is a problem in all states, the specific incident rate for Oregon is 1.2 / 100,000. This is above the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in OR, recent OR mesothelioma-related court cases, mesothelioma specialists in OR and potential asbestos hotspots in Oregon.

[doptab title=”Overview”]

Oregon Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Oregon

Oregon Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Oregon Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Oregon Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

[doptab title=”Treatment and Research”]


[dopaccordion title=”Fletcher, William S. Southwest Oncology Group
Grant: 2U10CA046113-06″ icon=27 activeicon=28]

Abstract: The specific purpose of this application is to obtain continued funding to support a multi-disciplinary program to conduct clinical research with cancer patients through participation in the Southwest Oncology Group (SWOG). This approach to cancer management is unique in this portion of the Pacific Northwest and provides contemporary treatment alternatives to an otherwise relatively isolated population. Specifically, the program proposes to: 1. Combine the disciplines of Surgical, Medical, and Radiation Oncology, Pathology, Immunology and Nursing Oncology in a synergistic attack on clinical cancer management by participation in SWOG protocols. 2. Participate in SWOG Phase II, III, and adjuvant studies. 3. Develop and conduct pre-clinical and clinical pilot studies for possible use by the SWOG. Such studies will include, but are not limited to, the neuroendocrine control of breast and prostatic cancer, regional chemotherapy by perfusion, infusion, and chemoembolization, suppression of functioning tumors of the gastrointestinal tract and other cancers by the synthetic somatostatin (Octreotide), multiple modality therapy in the treatment of tumors such as alveolar soft part sarcoma metastatic to lung, retroperitoneal sarcomas and mesothelioma of the pleura, and the genetics of hematopoietic growth factors. 4. Provide core laboratory support and suitable administrative facilities for the clinical evaluation of various techniques for the neuroendocrine control of cancer. 5. To modernize data entry and management capabilities by computerization as this capability develops within SWOG. 6. Further define chemosenstivity testing for determination of drug and hormone sensitivity in solid tumors. 7. To return SWOG information and expertise to the local area by consultation, lecture and symposia for the benefit of regional physicians and patients.

Tags:Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Breast Neoplasm, Cancer Registry /resource, Clinical Study /trial, Colon Neoplasm, Computer Data Analysis, Cooperative Study, Gastrointestinal Neoplasm, Health Care Referral /consultation, Hematopoietic Growth Factor, Hormone Therapy, Human Therapy Evaluation, Immunomodulator, Intraarterial Administration, Meeting /conference /symposium, Melanoma, Mesothelioma, Metastasis, Neoplasm /cancer Remission /regression, Neuroendocrine System, Pancreas Neoplasm, Perfusion, Peritoneum Neoplasm, Pleural Neoplasm, Prostate Neoplasm, Sarcoma, Somatostatin Cancer Information System, Human Subject

  • Followup Grant: 5U10CA046113-07
  • Followup Grant: 5U10CA046113-08
  • Followup Grant: 5U10CA046113-10
  • Followup Grant: 2U10CA046113-11
  • Followup Grant: 5U10CA046113-12
  • Followup Grant: 5U10CA046113-14
  • Followup Grant: 5U10CA046113-15
  • Followup Grant: 5U10CA046113-16

[dopaccordion title=”Bright, Robert K. T Cell Focused Cancer Vaccines In Murine Tumor Models
Grant: 7R29CA077351-03″ icon=27 activeicon=28]

Abstract: DESCRIPTION: (Applicant’s Abstract) One in six people will die of cancer. the systemic nature, recall ability and exquisite specificity of the immune system makes immunotherapy an attractive prospect for cancer treatment. Hepatocellular carcinoma, cervical carcinoma, various leukemias and lymphomas all have proposed viral etiologies. Viral encoded tumor specific antigens make viral associated tumors strong candidates for immunotherapy. Recent studies have described the presence of simian virus 40 (SV40)-like gene sequences and proteins (specifically the large tumor antigen: SV40 Tag) in human osteosarcomas, glioblastomas, ependymomas and malignant pleural mesotheliomas (MPM), demonstrating SV40 association with certain human malignancies. To facilitate the development of human clinical protocols for the immunotherapy of SV40 associated human malignancies, the proposed study will employ an SV40 murine tumor system to evaluate the efficacy of CTL transfer therapies and peptide based vaccines designed to target an immune response to SV40 Tag expressing tumors in vivo. Briefly, SV40 Tag specific CTL will be generated by immunization of Balb/c mice with SV40 Tag gene constructs and the epitope specificity determined by using selected H-2d restricted synthetic peptides representing potential CTL epitopes on SV40 Tag. These CTL will be utilized to examine the ability of adoptively transferred T cells to protect against tumor challenge in syngeneic mice. Further, selected synthetic peptides will be examined for the ability to actively induce protective tumor immunity in vivo. Completion of this study will provide valuable information on the active induction of tumor destructive immunity involving SV40 Tag-epitope specific CTL in vivo. Moreover, the information generated using the murine SV40 tumor model will expedite the development of reagents and clinical trials designed to examine SV40 Tag specific immunotherapies for SV40 associated human malignancies.

Tags:Cytotoxic T Lymphocyte, Neoplasm /cancer Immunology, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Vaccine, Nonhuman Therapy Evaluation, Simian Virus 40, Tumor Antigen Mhc Class I Antigen, Astrocytoma, Disease Model, Drug Screening /evaluation, Ependymoma, Immunogenetics, Mesothelioma, Neoplastic Cell, Neoplastic Transformation, Osteosarcoma, Synthetic Peptide, Virus Antigen, Virus Genetics, Virus Protein, Virus Related Neoplasm /cancer Active Immunization, Laboratory Mouse

  • Followup Grant: 5R29CA077351-04
  • Followup Grant: 5R29CA077351-05


Clinical Trials

[dopaccordion title=”Active, not recruiting Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma

Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride

More Information

[dopaccordion title=”Suspended Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information

[dopaccordion title=”Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information


[dopaccordion title=”Active, not recruiting AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

[dopaccordion title=”Recruiting Collecting Tumor Samples From Patients With Gynecological Tumors” icon=27 activeicon=28]

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

[dopaccordion title=”Completed Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases” icon=27 activeicon=28]

Condition: Life Threatening Diseases
Intervention: Drug: Imatinib mesylate
More Information


[doptab title=”Doctors and Hospital”]

Hospitals and Cancer Centers

We do not have any doctors or cancer centers for this state at the moment.

[doptab title=”Cases”]

Mason v. Mt. St. Joseph, Inc.
A133639, COURT OF APPEALS OF OREGON, March 13, 2008, Argued And Submitted, March 4, 2009, Filed

Dahlke v. Cascade Acoustics, Inc.
A127280, COURT OF APPEALS OF OREGON, June 13, 2007, Argued And Submitted, November 7, 2007, Filed

Union Bank of Cal., N.A. v. Copeland Lumber Yards, Inc.
A131135, COURT OF APPEALS OF OREGON, February 21, 2007, Argued And Submitted, Banks High School, Banks. , June 13, 2007, Filed

Solberg v. Tice Elec. (In re Solberg)
A129565, COURT OF APPEALS OF OREGON, December 21, 2006, Argued And Submitted, May 2, 2007, Filed

Weihl v. Asbestos Corp., Ltd.
A122068 , COURT OF APPEALS OF OREGON, June 6, 2005, Argued And Submitted , February 15, 2006, Filed

West v. Allied Signal, Inc.
A122831 , COURT OF APPEALS OF OREGON, March 31, 2005, Argued And Submitted , June 15, 2005, Filed

[doptab title=”Lawyers”]

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.